BIOPROCESS VALIDATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The Bioprocess Validation Market size is expected to reach US$ 460.9 million by 2030, from US$ 882.4 million in 2023, growing at a CAGR of 9.7% during the forecast period. Bioprocess validation refers to the process of demonstrating and ensuring that a biopharmaceutical manufacturing process consistently and reliably produces products that meet pre-determined quality standards and regulatory requirements. It involves validating critical process parameters, equipment, analytical testing methods, cleaning procedures, computer systems, and facilities. Bioprocess validation is crucial for ensuring drug safety, efficacy and quality. The key drivers boosting the bioprocess validation market growth include increasing R&D investments in pharmaceutical and biotechnology industries, growth of the biosimilars and biologics market, and favorable government regulations, among others.

The bioprocess validation market is segmented by test type, process type and end user and region. By test type, the market is segmented into extractable testing services, microbiological testing services, physiochemical testing services, integrity testing services and others. The test type segment accounted for the largest share in 2022. This is attributed to the high adoption of bioprocess instruments like bioreactors and chromatography systems by biopharmaceutical companies for validating their manufacturing processes.

Analyst View:

• The bioprocess validation market is poised to grow significantly over the coming years. North America and Europe currently dominate the market due to stringent regulatory requirements for bioprocess validation. However, Asia Pacific is expected to show fastest growth with expanding biosimilar and biologics manufacturing capabilities in countries like China, India and South Korea.
• The market is primarily driven by the increasing adoption of monoclonal antibodies and recombinant proteins for treatment of various chronic diseases. As bioprocesses become more advanced and complex, the need for thorough validation of these processes will continue to rise. Additionally, continued support from regulatory bodies to ensure product quality and safety will also drive adoption of bioprocess validation solutions.
• However, the market also faces restraints from the high costs associated with validation procedures. Established validation protocols coupled with lack of trained professionals pose further challenges.
• Nevertheless, emergence of cell therapy and gene therapy presents major growth opportunities in the market. Contract service providers are focusing on integrating digital tools for continuous process monitoring and real-time release testing. Adoption of advanced analytics and modelling techniques could help optimize bioprocesses and facilitate timely product approvals. Overall, with the rising biopharmaceutical R&D expenditure and growing need to ensure consistent process performance, the demand for bioprocess validation solutions is expected to increase tremendously in the coming

Bioprocess Validation Market Regional Insights:

• North America is expected to be the largest market for bioprocess validation during the forecast period, accounting for over 2% of the market share in 2022. The growth of the market in North America is attributed to the presence of leading biopharmaceutical companies, high R&D investments, and stringent regulatory requirements for bioprocess validation in the region.
• Europe is expected to be the second-largest market for bioprocess validation, accounting for over 5% of the market share in 2022. The growth of the market in the region is attributed to increasing bioproduction activities, rising focus on life science research, and favorable government funding in Europe.
• Asia Pacific is expected to be the fastest-growing market for bioprocess validation, exhibiting a CAGR of over 19.3% during the forecast period. The growth of the market in Asia Pacific is attributed to the expanding biopharmaceutical manufacturing sector, increasing investments in R&D infrastructure, and rapid growth in outsourcing services in the region.

Figure 1. Global Bioprocess Validation Market Share (%), by Region, 2023

To learn more about this report, request a free sample copy

Bioprocess Validation Market Drivers:

• Increasing R&D investments in biopharmaceuticals: The biopharmaceutical industry has been witnessing substantial growth in R&D expenditures over the past decade. Several biopharma companies have robust clinical pipelines with increasing focus on developing novel biologics and biosimilars. This rise in biologic drugs development has subsequently fueled the need for extensive process characterization and validation during preclinical and clinical manufacturing. Moreover, the complexity of bioprocesses for novel modalities such as cell and gene therapies demand greater validation stringency to ensure drug safety and efficacy.
• Growth of biologics and biosimilars market: The rapidly expanding market for biologic drugs and biosimilars is a major factor driving bioprocess validation activities. The approval of high-value biologics for cancer and autoimmune diseases has further escalated bioproduction volumes across the industry. This creates significant demand for validated manufacturing processes and analytics to ensure seamless scale-up and product quality compliance.
• Increasing outsourcing by biopharmaceutical firms: Many biopharma firms are strategically outsourcing various bioprocessing activities, including validation services to contract companies. Contract manufacturing organizations (CMOs) are enhancing their service offerings to provide end-to-end validation support for their sponsors' processes and products. Additionally, the expertise provided by CMOs in designing and implementing validation protocols aligned with regulatory expectations is encouraging sponsors to increasingly leverage outsourcing.
• Growing bioprocess infrastructure investments: Substantial investments are being made by biopharma companies to build advanced bioprocessing facilities and augment their manufacturing capacities. The expansion of production capacities for APIs and biologics is necessitating significant validation requirements. Furthermore, upgrading legacy facilities to enhance process efficiency also requires revalidation of equipment, methods and infrastructure. This is contributing significantly to bioprocess validation demand. Moreover, market players have been investing for launching new resource centers and this is expected to drive the growth of the global bioprocess validation market over the forecast period. For instance, in 2022, Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, launched its new Bioprocess Resource Center, an information source for the bioprocess industry.

Bioprocess Validation Market Opportunities:

• Automation and data analytics: Automation technologies like robotics and interconnected IoT systems offer enormous opportunities for optimizing and accelerating bioprocess validation activities. Advanced analytics combined with automation can enhance monitoring, facilitate continuous verification, and allow rapid data-driven decision making during validation. Data management technologies like blockchain also foster data security and transparency between outsourcing partners.
• Single-use systems integration: Single-use technologies are witnessing increased adoption in bioprocessing owing to advantages such as flexibility, reduced costs, and quicker implementation. Integrating single-use components into critical process steps provides avenues for faster and more efficient validation. Moreover, the modular nature of single-use systems allows additional validation when new disposable components are introduced into existing validated processes.
• Virtualization and in silico modeling: In silico modeling tools allow the simulation of bioprocesses digitally for optimization and troubleshooting. Virtual validation using mechanistic models and artificial intelligence can potentially reduce dependency on extensive real-time physical trials. By digitally emulating manufacturing processes, biopharma players can refine validation protocols and focus physical runs on edge cases. This can significantly improve productivity and speed.
• Collaborative partnerships: Bioprocessing firms are entering strategic partnerships with technology providers, CMOs, laboratories, and research institutes to enhance their validation competencies and testing capacities. Collaborative frameworks allow leveraging partners' specialized expertise and infrastructure for method development, characterization analytics, automation integration, and other validation needs.

Bioprocess Validation Market Trends:

• Digitization and paperless validation: A significant trend is the move towards paperless validation leveraging automation, electronic logbooks and specialized IT infrastructure. Digital tools allow centralized management of validation lifecycle data in a secure and compliant manner. They also enhance accessibility to historical records and real-time information sharing between cross-functional teams to support continuous verification.
• Adopting quality by design (QbD) principles: Biopharma firms are increasing the use of quality by design approaches for validation. QbD facilitates deeper process understanding for establishing control strategies and defining design spaces to ensure consistent quality. This science-based methodology with real-time release allows shifting validation from demonstrating compliance to continuous process verification.
• Enhanced analytical testing: Advanced analytical tools like high-resolution mass spectrometry are gaining traction for characterizing biochemical properties, impurities and degradation products during validation. Additionally, analytical assay kits are being developed for specialized quantification of critical quality attributes like host cell DNA and residual proteins.
• Combining regulatory compliance: Biopharmaceutical companies are adopting more integrated quality and validation strategies for their processes to allow combined compliance with multiple regulatory authorities. Unified validation protocols are being designed using quality risk management principles to meet requirements from FDA, EMA and ICH guidelines.

Bioprocess Validation Market Restraints:

• High capital investment requirements: Comprehensive bioprocess validation requires significant investment in equipping facilities with advanced instruments, automation systems and IT infrastructure. Smaller biopharma players and startups may not have adequate capital for large validation expenditures. This may restrain them from implementing validated processes, limiting growth opportunities.
• Lengthy product approval timelines: The end-to-end validation of bioprocesses along with technology transfer activities can prolong regulatory approval timelines of biologics by several months. The extensive trials involved makes introducing modifications to optimize processes very cumbersome as well. The resulting long product launch timelines can restrict growth potential for manufacturers.
• Undefined regulations for emerging markets: Uncertainties around regulatory expectations for bioprocess validation in high-growth emerging markets like China, Brazil and South Korea pose challenges for manufacturers. Undefined validation norms force companies to bear additional costs to revalidate processes to comply with local requirements when expanding into these markets.

Recent Developments:

New product launches:

• In January 2019, Sartorius Stedim Biotech, an international pharmaceutical and laboratory equipment supplier, which offers solutions for the biopharmaceutical industry and laboratories, launched ambr 250 modular, an automated mini bioreactor system for bioprocess development applications like cell line screening, process optimization and scale-up modeling

Acquisition and partnerships:

• In January 2021, Sartorius AG, an international partner for biopharmaceutical research and industry, acquired a majority stake in CellGenix, a leading global supplier of GMP-grade cell culture components, to expand its cell culture media portfolio
• In June 2020, Thermo Fisher Scientific, a biotechnology company, acquired Henogen, a viral vector CDMO, to expand capabilities for cell and gene therapy development and manufacturing

Figure 2. Global Bioprocess Validation Market Share (%), by Test Type, 2023

To learn more about this report, request a free sample copy

Top companies in Bioprocess Validation Market:

• Sartorius Stedim Biotech
• Merck KGaA
• Pall Corporation
• Cobetter Filtration Equipment
• Toxikon Corporation
• DOC S.r.l.
• MEISSNER FILTRATION PRODUCTS
• Thermo Fisher Scientific
• SGS SA
• Eurofins Scientific
• Lonza Group
• ProBioGen AG
• Charles River Laboratories
• Pacific BioLabs
• Gibraltar Laboratories
• Nelson Laboratories
• BioProcess Technology Consultants
• CMIC HOLDINGS Co., Ltd
• Cytovance Biologics
• Wuxi Biologics

*Definition: Bioprocess validation refers to the documented evidence and assurance that a biopharmaceutical process consistently and reliably produces products that meet predetermined specifications and quality standards. It involves validating all critical aspects of bioproduction including equipment, facilities, utilities, processes, analytical testing methods and automation systems as per good manufacturing practices and regulatory guidelines. Bioprocess validation is an essential part of biologics manufacturing and is crucial for ensuring product quality, efficacy and safety. It builds confidence that the manufacturing process eliminates variance and consistently delivers high quality outputs.

Few Other Promising Reports in Biotechnology Industry:

Biologics Outsourcing Market

Biologics Market

Biopharmaceuticals Market

Biosimilars Market